Next Generation Sequencing Market Analysis

Next Generation Sequencing Market Overview

Next Generation Sequencing Market Size was valued at USD 12.85 billion in 2023 and is projected to grow from USD 14.68 Billion in 2024 to USD 39.25 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.54% during the forecast period (2024 - 2032).

Increasing application of next generation sequencing and increasing genome mapping & funding programs are fueling the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

In partnership with Tecan, TurBOT beta access was launched by Oxford Nanopore in December 2023. The products are expected to be delivered to buyers in Q1 2024. TurBOT is a desktop device that is capable of efficient base-calling, automated extraction, data analysis, and library preparation for multiple samples at the same time.

A memorandum of understanding was signed between Illumina and the African Society for Laboratory Medicine in December 2023 to increase genomics accessibility, which can help fight infectious diseases within Africa.

HaploX partnered with Illumina in China to develop sequencing instruments domestically in December 2023.

In November 2023, MedGenome announced the De Novo Genome Assembly and Annotation grant together with PacBio. These research grants will accelerate new developments within the sector.

Starting from November 2023, all workflow of long-read sequencing has been optimized through Yourgene Health’s collaboration with PacBio. For this purpose, Pico approved the LightBench instrument made by Yourgene Health to enable the size selection of long DNA fragments.

IDT introduced its xGen NGS products (including primers, adapters, and universal blockers) for the Ultima Genomics UG platform in September 2023.

The first partner that joined Qiagen’s QIAseq Platform Partnership program was medical data-analysis provider SOPHiA GENETICSTM, as it was named in March 2023 during the introduction of this initiative. This will bring together its QIAseq reagent technology for next-generation sequencing (NGS) with the SOPHiA DDMTM digital analytics platform in a partnership with medical data-analysis provider SOPHiA GENETICSTM as it was named on March 2023 during the introduction of this initiative.

Thermo Fisher Scientific announced CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer on March 2nd, which is an automated next-generation sequencing (NGS) platform that provides results within one day. In addition to being suitable for diagnostic purposes by clinical laboratories, this technology is fully validated and permits the same instrument to be employed in both diagnostic testing and clinical research.

Genes2Me shared a range of NGS-based oncology, personalized medicine, and hereditary illness panels in May 2022. These panels are available for all common Illumina, Thermo Fisher ION, and MGI NGS platforms and have been designed and validated.

Illumina, a DNA sequencing company in Europe, introduced a new in vitro diagnostic test that can determine different cancer mutations and enable patients to get personalized treatments.

The order of the nucleotides in the entire genome can be determined using next-generation sequencing (NGS), a massively parallel sequencing method that provides flexibility, ultra-high throughput, and fast speed. As it includes preparing the material for the following sequencing reaction, DNA pre-sequencing constitutes one of the most important processes in the general sequencing protocol. This has also made the services the most appealing and lucrative market category for NGS. The increasing acceptance of genetic tests, declining expenses for sequencing through NGS, new guidelines, and changes in health insurance reimbursement rules are all expected to contribute to the services segment's expected impressive expansion over the projection period. The market is segmented into diagnostics, studies, and other applications.

Due to the growing use of genetic testing, increasing demand for cancer analysis, and the rise in service providers, the diagnostic segment is predicted to make up a significant percentage of the next-gen sequencing market. NGS is increasingly being incorporated into clinical laboratory evaluation, testing, and illness diagnosis. Pharmacogenomics has extensively used NGS to speed up the drug development process. Government organizations are also sequencing millions of genomes to advance science and find new ways to diagnose and treat diseases, including rare disorders and other afflictions.

Additionally, increased reimbursement coverage and active government support for such diagnostic tests are anticipated to open new market expansion potential. Additionally, it is projected that the launch of high-budget genomics projects, increasing research, and the rising frequency of chronic diseases will all contribute to the market's growth throughout the projection period. Due to increased global investment in NGS technologies, NGS research and development has reached unprecedented heights. The market is expanding due to rising NGS usage and increased demand for genomic mapping programs.

News

WHO quickly communicates about using focused next-generation sequencing for tuberculosis medication resistance diagnosis. The Rapid Communication comes out ahead of updated WHO solidified guidelines for TB diagnosis, which are expected to be published later in 2023, to alert national TB programs and other participants to significant changes anticipated in the options for TB drug resistance detection and to facilitate quick transition and planning at the national level. Additional guidance, including step-by-step instructions on introducing sequencing and the most recent mutation catalog, will also be made public soon.

Next Generation Sequencing Market Trends

• 
  

  Increasing application of next generation sequencing boosts market growth

  
  

In recent years, next generation sequence (NGS) has found tremendous applications in research and clinical use. Some of the key areas in which NGS finds various applications include oncology, clinical investigation, reproductive health, human leukocyte antigen typing or immune system monitoring, metagenomics, epidemiology, drug development, agrigenomics, forensics, and consumer genomics. In clinical settings, NGS is used to diagnose various disorders. In addition, it is widely used in identifying mutation targets for targeting therapy and identifying a high-risk population for certain hereditary cancers. Moreover, the clinical application of NGS includes tests for tumor mutation burden, a potential biomarker associated with response to immune checkpoint inhibitor therapies, tests for microsatellite instability, and tests for mutations from liquid biopsy.

Continuous decline in the cost of sequencing data increases research activities in biological research and clinical research. Innovations in the field of genomics have grown over the past quarter-century, which has led to substantial reductions in the cost of sequencing a human genome. The decline in the price of sequencing helps genetic research, increases human genome sequencing research activities, and reduces the genomic sequencing test price. Genomic sequencing has more applications in the diagnostic and pharmaceutical industries. This decline in cost is likely to increase the demand for genome sequencing products and services during the forecast period.

Next Generation Sequencing Market Segment Insights

Next Generation Sequencing Technology Insights

The next generation sequencing market segmentation, based on technology, includes whole exome sequencing targeted sequencing and resequencing, and whole genome sequencing. Furthermore, targeted sequencing and resequencing bifurcated into DNA-based targeted sequencing & resequencing and RNA-based targeted sequencing & resequencing. The whole exome sequencing segment held the majority share in 2021 contribution to around ~40-42% in respect to the next generation revenue. This is owing to the technological advancements that allow for the rapid sequencing of large amounts of DNA. In addition, whole-exome sequencing has been a valuable method for researchers. Researchers use exome sequencing in research to identify cancer-associated gene expression profiles. Continued study of exome sequences can help determine whether new genetic variations are associated with health conditions, which will aid disease diagnosis in the future.

December 2021: F. Hoffmann-La Roche Ltd (US) launched the AVENIO Edge System, a key component of the company's strategy to enhance sequencing technology. The system provides a fully automated, integrated sequencing solution based on best-in-class core capabilities.

January 2020: Illumina, Inc. (US) partnered with F. Hoffmann-La Roche Ltd (Switzerland) to accelerate the adoption of genomics.

Next Generation Sequencing Workflow Insights

The next generation sequencing market segmentation, based on workflow, includes pre-sequencing, sequencing, and data analysis. Furthermore, pre-sequencing has been segmented into NGS library preparation kits, NGS semi-automated library preparation kits, NGS automated library preparation kits, and clonal amplification moreover, data analysis further segmented by type into NGS primary data analysis, NGS secondary data analysis, and NGS tertiary data analysis. The pre-sequencing dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. The sequencing is a critical step of the workflow and is a capital-intensive procedure that, in turn, accounts for a higher revenue generation. The last step in the next generation sequencing workflow is processing, analysis, and interpretation of the sequencing data generated.

Next Generation Sequencing Application Insights

Thenext generation sequencing market data has been segmented by application into oncology, clinical investigation, reproductive health, human leukocyte antigen typing or immune system monitoring, metagenomics, epidemiology and drug development , agrigenomics and forensics, consumer genomics, and others. The oncology has been further segmented into diagnostics and screening, companion diagnostics, and others. The clinical investigation by type includes infectious diseases, inherited diseases, idiopathic diseases, and non-communicable diseases, and others. Moreover, reproductive health has been segmented into non-invasive prenatal testing, pre-implantation genetic testing, newborn or genetic screening, single gene analysis, and others. The reproductive health segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Next generation sequencing technology is increasingly being adopted in the field of reproductive health. According to the article published by Thermo Fisher Scientific (US) in March 2021, 80% of children born with a recessive disorder are not aware of a family history of that condition. NGS supports driving fast, accurate, and comprehensive detection of a large spectrum of genetic variants in researching disease risk factors for inherited disorders. It also enables research and analysis of various genomic features from a single sequencing run, including copy number variants, single nucleotide variants (SNVs), and structural variants.

January 2021: Illumina, Inc. (US) expanded oncology partnerships with Bristol Myers Squibb (US), Kura Oncology (US), Myriad Genetics (US), and Merck KGaA (Germany) to advance comprehensive genomic profiling.

Figure 2: Next Generation Sequencing Market, by Application, 2021 & 2030 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Next Generation Sequencing End User Insights

Based on end user, the next generation industry has been segmented into hospitals & clinics, diagnostic laboratories, pharmaceutical and biotechnology companies, and academic and research institutes. The diagnostic laboratories segment dominated the market in 2021, while academic & research institutes is projected to be the fastest-growing segment during the forecast period. There are two types of NGS tests for clinical diagnosis, namely, laboratory-developed tests (LDTs) and in-vitro diagnostics (IVDs). Adopting LDTs for routine clinical diagnostics requires ease of use for laboratories and quick turnaround to ensure timely decision-making by clinicians. Both IVDs and LDT are easily reproducible, attainable, reliable, and cost-effective results in the adoption of NGS technology.

February 2021: Qiagen (Germany) collaborated INOVIO Pharmaceuticals (US) to develop liquid biopsy-based companion diagnostic solutions based on next generation sequencing (NGS) technology to supplement INOVIO's medicines.

News

Infectious disease detection technique plasma metagenomic next-generation sequencing (mNGS) was the subject of a recent study published in the Open Forum Infectious Diseases Journal. MNGS uses high-throughput sequencing techniques to detect DNA or RNA swiftly and precisely from suspected infections. NGS can be performed on any patient sample, although for easily accessible samples like the patient serum, microbial cell-free DNA (mcf-DNA) is preferred. Mcf-DNA is released by dead and dying cells, and it has been found in individuals with active infections to contain genomic DNA fragments from pathogenic organisms.

Next Generation Sequencing Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America next generation market accounted for USD 4.19 billion in 2021 and is expected to exhibit an 18.15% CAGR during the study period. This large market share is due to developed healthcare infrastructure, increasing incidence of cancer, and increasing application of Next Generation Sequencing in precision medicine in the region. In addition, the rise in the adoption rate of NGS platforms for analysis and diagnostics of rare diseases and for identifying therapeutic targets, the emergence of rapid and advanced sequencing technologies reduced the costs of sequencing, growing demand for NGS methodologies in genomics research, and in clinical diagnosis is further driving the market in this region.

Further, the major countries studied are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: NEXT GENERATION MARKET SHARE BY REGION 2021 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe next generation market accounts for the second-largest market share due to an increasing technological advancement in sequencing, extensive use of genomics for medical applications, and increasing healthcare expenditure High-throughput sequencing, most widely considered the "next-generation" sequencing (NGS), is integrated into routine clinical practice due to the numerous technical and functional developments. The increased technological advancement leads to the development of highly efficient next generation sequencing and, in turn, market growth. Furthermore, the Germany next generation market held the largest market share, and the France next generation market was the fastest growing market in the Europe region

The Asia-Pacific Next generation market is expected to grow at a CAGR of 20.63% from 2022 to 2030. owing to the increasing technological developments in next generation sequencing and price reduction in sequencing technology, growing incidence of cancer, and increasing applications of next generation sequencing in cancer research. Emerging economies, such as China, Japan, and India, have accepted the next generation technology due to its lower cost. The cost of sequencing in India has reduced over the years owing to factors such as advances in the field of genomics and the development of different methods and strategies for sequencing. Moreover, China next generation market held the largest market share, and the India next generation market was the fastest growing market in the Asia-Pacific region.

Next Generation Sequencing Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the next generation market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the next generation industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Becton Eurofins Scientific (US) is the leader in environment, food, pharmaceutical & cosmetic product testing, forensics, discovery pharmacology, advanced material sciences, and agroscience contract research services. The company is also an independent market leader in genomics and supports clinical studies and biopharma contract development and manufacturing. In May 2021, Eurofin launched of its "ARTIC SARS-CoV-2 Whole Genome Sequencing" service, which includes NGS and detailed reporting for universal end-to-end surveillance of pandemic development, tracking the emergence and dynamics of existing and new mutational variants of concern.

Additionally, Illumina, Inc. (US) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale genetic variation and function analysis. The company's portfolio includes integrated sequencing and microarray systems, consumables, and analysis tools designed to accelerate and simplify genetic analysis. In January 2022, Illumina Inc. partnered with Agendia N.V. (Netherlands), a world leader in oncology for breast cancer, to co-develop in vitro diagnostic (IVD) tests for oncology testing. This partnership is intended to advance next generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina's approach to IVD partnerships in oncology.

Key Companies in the Next generation sequencing market includes

• Becton Eurofins Scientific (US)


• Illumina, Inc. (US)


• Genome Life Sciences (India)


• GenScript (US)


• Thermo Fisher Scientific, Inc. (US)


• Qiagen (Germany)


• PerkinElmer, Inc. (US)


• F. Hoffmann-La Roche Ltd (Switzerland)


• Pacific Biosciences of California, Inc. (US)


• Xcelris Genomics (India), among others

Next Generation Sequencing Industry Developments

February 2021: Qiagen (Germany) and INOVIO Pharmaceuticals (US) signed a collaboration to develop liquid biopsy-based companion diagnostic solutions based on Next Generation Sequencing (NGS) technology to supplement INOVIO's medicines.

June 2021: PerkinElmer, Inc. (US) acquired SIRION Biotech GmbH (Germany), a leading viral vector-based technology developer that increases cell and gene therapy delivery performance. This acquisition contributes to the expansion of the company’s reach in next-generation market in Germany.

January 2019: Qiagen (Germany) acquired N-of-One, Inc. (US), a privately-held US molecular decision support company and a pioneer in clinical interpretation services for complex genetic data. N-of-One (US) creates case-specific reports using data provided by molecular assays, such as Next Generation Sequencing (NGS) technology. As a result, this acquisition contributes to the growth of the Next Generation Sequencing market in the US.

Next Generation Sequencing Market Segmentation

Next Generation Sequencing Technology Outlook

• Whole Exome Sequencing


• Targeted Sequencing and Resequencing
  
  
  
  • DNA-based Targeted Sequencing & Resequencing
  
  
  • RNA-based Targeted Sequencing & Resequencing
  
  
  
  


• Whole Genome Sequencing

Next Generation Sequencing Workflow Outlook

• Pre-sequencing
  
  
  
  • NGS Library Preparation Kits
  
  
  • NGS Semi-Automated Library Preparation Kits
  
  
  • NGS Automated Library Preparation Kits
  
  
  • Clonal Amplification
  
  
  
  

• Sequencing


• Data Analysis
  
  
  
  • NGS Primary Data Analysis
  
  
  • NGS Secondary Data Analysis
  
  
  • NGS Tertiary Data Analysis
  
  
  
  

Next Generation Sequencing Application Outlook

• Oncology
  
  
  
  • Diagnostics and Screening
  
  
  • Companion Diagnostics
  
  
  • Others
  
  
  
  


• Clinical Investigation
  
  
  
  • Infectious Diseases
  
  
  • Inherited Diseases
  
  
  • Idiopathic Diseases
  
  
  • Non-Communicable Diseases
  
  
  • Others
  
  
  
  


• Reproductive Health
  
  
  
  • Non-invasive Prenatal Testing
  
  
  • Pre-implantation Genetic Testing
  
  
  • Newborn or Genetic Screening
  
  
  • Single Gene Analysis
  
  
  • Others
  
  
  
  


• Human Leukocyte Antigen Typing or Immune System Monitoring


• Metagenomics, Epidemiology and Drug Development


• Agrigenomics and Forensics


• Consumer Genomics


• Others

Next Generation Sequencing End User Outlook

• Hospitals & Clinics


• Diagnostic Laboratories


• Pharmaceutical and Biotechnology Companies


• Academic and Research Institutes

Next Generation Sequencing Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America